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(29%) developed a thrombotic thrombocytopenic 
purpuraAnicroangiopathic hemolytic anemia syndrome or an 
acute hemolytic reaction that was treated with plasmapheresis or 
red cell exchange. Twenty-one of 30 (70%) evaluable patients 
developed grade II-IV acute GVHD. Of these, 62% had grade 
III-IV acute GVItD. Sixteen of 21 (76%) evaluable patients, 
developed chronic GVHD with 63% of those patients having 
extensive chronic GVHD. The day 100 survival was 68%. Ten 
patients are alive at a median of 67.6 months (range: 45.2-82.3), 
for an overall survival of 32%. These results indicate that, in con- 
trast to its effects after allogeneic BMT, single-agent tacrolimus 
does not adequately prevent GVHD after related allogeneic 
PBSCT. 
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PHASE II STUDY OF DENILEUKIN DIFTITOX (ONTAK) IN THE 
TREATEHENT OF STEROID RESISTANT ACUTE GRAFT VERSUS HOST 
DISEASE (AGVHD) 
Shat~g',~nes~, P.; Bachier, C.; G'dmley, M.; LeMaid'tre, C.F. Texas 
Transplant lnstitute, San Anto~lio, TX. 
AGVHD is one of the pricipal complications of allogeneic 
heluatopoietic stem cell transplantation. Ontak is a recombi- 
nant DNA derived cytotoxic fusion protein designed to direct 
the cytocidal action of diphtheria toxin to cells with high affin- 
ity of the IL-2 receptor. We designed a phase II trial to exam- 
ine the Ontak in patients (pts) with steroid resistant AGVHD. 
Steroid resistance was defined as treatment with 2mg/kg of 
methylprednisolone and progressive disease after 3 days or sta- 
ble disease after 7 days. Ontak treatment was 4.Smcg/kg/day 
IV for 5 days followed by the same dose weekly for 4 weeks. 
Four pts have been treated to date. Pt #I had stage 3 skin and 
stage 4 GI AGVHD that improved to stage 1 skin and stage 1 
GI by day 5 of the Ontak. Ontak was held in this pt because of 
a low albumin and fluid retention. GVHD recurred 4 weeks 
after Ontak was held and, despite treatment with inflixamab, 
GVHD progressed and the pt died of psuedonmnas sepsis. Pt 
#2 had stage 3 skin AGVHD that responded completely by day 
5 of the Ontak and finished 3 of the 4 weekly treatments, with 
the last treatment held for pancytopenia. Pt #3 had stage 4 GI 
and conjuctival AGVHD that completely resolved by day 5 of 
Ontak and finished all treatments. Pt #4 had stage 4 liver, 3 
skin, and 4 GI AGVHD that progressed after the first 5 day 
infusion of Ontak and was taken off study and treated with 
inflixilnab with an improvement to stage 3 liver, 0 skin, and 4 
GI AGVHD. Pt #4 had a generalized tonic-clonic seizure on 
day 2 of the Ontak infusion that was felt to be related to 
cyclosporine and completed the Ontak infusion with no fur 
ther neurologic sequalae. Pt #4 also developed isseminated 
adeuovirus. Pts #2 and #3 had grade III hematologic toxicity 
that was felt to be multifactorial and both also had bacterial 
upper respiratory tract infections that were treated and 
resolved. Patient #3 had CMV reactivation that was pre-emp- 
tively treated with valgancyclovir and resolved. Pts #2 and #3 
are both greater than 100 days from the start of the Ontak 
treatment and have been tapered to less than 0.5mg/kg or 
steroids while remaining on FK506 with no evidence of 
AGVHD. In conclusion, the low dose of Ontak used in this 
study appears active in AGVHD with acceptable toxicity. Fur- 
ther study to assess infection risk, response rates, and patient 
survival are warranted. .... 
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SELECTIVE DEPLETION OF HUMAN GVH-REACTIVE T-CELLS BY 
ANTI-CD95 MEDIATED ACTIVATION-INDUCED CELL DEATH OR VIA 
THE T-CELL ACTIVATION ANTIGEN CD69 FOR PREVENTING GRAFT- 
VERSUS-HOST DISEASE IN ALLO-BMT 
Norm, M.; Tnbbe, i.; Hnber, C.; Hartwig, U.F. Dept. of Hematology, 
Mamz, GelwzaJTy. 
Depletion of T-cells from allogeneic bone marrow transplants 
(BMT) ameliorates GvHD but is associated with impaired 
engraftment, inmmnosuppression, a dabrogation of the benefi- 
cial graft-versus-leukemia effect (GvL). We, therefore, explored 
the possibility of separating alloreactivity from T lymphocytes 
mediating GvL-responses x vivo by selective depletion of GvH- 
reactive T-cells using CD95/CD178-mediated activation induced 
cell death (MCD) or via the T-cell activation antigen CD69. T- 
cells purified from human PBMC were stinmlated with fully-mis 
matched stimulators in an allogeneic mixed lymphocyte culture 
(MLC) in the presence of agonistic anti-CD95 mAb. Specificity of 
depletion was tested by consecutively monitoring CMV-pp65 spe- 
cific T-cells present in PBMC from seropositive donors before 
and after MCD. As reported earlier in a murine model, prolifera- 
tive responses ofalloreactive T-cells were reduced 65-90% in the 
presence of anti-CD95 reagents depending on the mAb used. 
ELISpot analysis revealed the retainment ofpp65-specific T-cells 
in the residual allogeneic T-lymphocyte population comparable to 
frequencies detected in normal controls. In comparative studies, 
elimination of alloreactive specificities by imnmnomagnetic sepa- 
ration using the T-cell activation marker CD69 resulted in 3 sub- 
sets ofT-cells. Restimulation ofCD69- cells (> 98%) as well as the 
CD69 + population and the CD69 dull cells retrieved from the wash- 
fraction with 1st party stimulators esulted in a substantial reduced 
proliferation of the CD69- cells as compared to he positive sub- 
set. The CD69 d~ll T-lymphocytes also showed residual alloreactiv- 
ity. Interestingly, monitoring for pp65-reactive T-cells by 
ELISpot analysis indicated that the majority of pp65-specific T- 
cells appeared to be enriched in the CD69 '1"11 population. Further 
studies on the efficacy, specificity and potential of retained allo- 
geneic T-cells to respond to l~mwn leukemia associated antigens 
in HLA-naislnatched as well as HLA-lnatched settings are in 
progress and will be discussed. 
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SERUM CYTOKINE PROFILES OF PATIENTS WITH ACUTE GVHD 
TREATED WITH METHYLPREDNISOLONE ALONE OR IN COMBINA- 
TION WITH INFLIXIMAB ARE DIFFERENT 
Lee, B.; Couvie/, D.; Shen, D.; Hhlze, L.; C,Oam, plin, R.; Re~tt, e~7, J.M. 
M.D.Anderson Uancer Center, Houston, TX. 
Graft-versus-host disease (GVHD) is a major problem for recip- 
ients of allogeneic blood and marrow transplantation. GVHD, 
mediated by TNF-alpha produced by activated mononuclear cells, 
can be treated with methylprednisolone (NIP) or in combination 
with Infli.'dmab (I), a chimeric human/lnouse anti-TNF antibody 
that interferes with the activity of TNF-alpha. Moreover, as acute 
GVHD (aGVHD) is linked to increases in the levels of inflamma- 
tory cytokines, we hypothesized that there would be a decrease in
inflammatory cytokines as patients achieved a complete response 
following treatment for aGVHD. Therefore, we collected sera 
from 52 patients with aGVHD who were randomized to one of 
two treatment arms to receive either methylprednisolone (MP) or 
MP plus Infli~mab (MP+I) once a week for 4 weeks. We meas- 
ured serum levels of IL-2, IL-6, IL-10, IL-12, TNF-alpha, and 
IFN-gamma pre-treatment and at weekly intervals thereafter for 5 
weeks on a subset of patients with aGVHD. We analyzed CTtokine 
data for 10 MP and 10 MP+I patients. The levels of IL-6, IL-10, 
, IL-12, and IFN-gamma before and after treatment were similar 
for both groups. The profiles of IL 2 and TNF2alpha levels over 
time however were different for the 2 groups. The levels of these 
cytokines in the MP+I group peaked in the first wo weeks of 
treatment and declined thereafter. Conversely, the levels of IL-2 
and TNF-alpha in the MP group were low in the first two weeks 
of treatment and increased thereafter. These preliminal T data sug- 
gest that there may be differences in the profiles of IL-2 and 
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TNF alpha in the two treatment arms and further study is needed 
to determine the significance of this observation. 
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ANALYSIS OF CD4+CD25 ÷ T REGULATORY CELL SURVIVAL AND 
FUNCTION FOLLOWING IN VITRO AND IN VIVO IRRADIATION 
Zi71~.Me~'~a~, Z.F.; Baez, a7.; Rodeos, M.; ~la~n~ole~ti, ~.;  Levy, R.R 
Microbiology m~d Immmmlogh U~ive'~sit3, of 3/Iiami &'hool of Medid~te, 
Miami, FL. 
Manipulating the host regulatory T cell compartment may be 
useful in BMT strategies for successful engraftment and anti- 
tumor responses. In order to investigate he effect of conditioning 
regimens on host CD4+CD25 + T regulatory cell function prior to 
BMT, highly purified populations of Tregs were produced from 
several mouse strains and exposed to varying levels of gamma irra- 
diation ex vivo. Following treatment, Tregs were co-cultured with 
CD4+CD25 rcsponders, accessory cells, and anti-CD3 mAb. At 
doses as low as 3.0 Gy, Tregs exhibited iminished capacity to 
regulate CD4+ T cell proliferation i~ vit*v. To assess the effect of 
the radiation on Treg survival, purified populations were exposed 
to doses front 3.0Gy to 9.0Gy and assessed by Annexin V staining. 
After 24 hrs., >90% of the Tregs were positive regardless of dose. 
Co-culture with accessory cells and stinmlation with anti-CD3 
during this time period could not rescue these cells from death. 
To examine cell survival following i*z vivo irradiation, splenic 
CD4+CD25 + cells were purified from mice immediately following 
3.0 or 9.0Gy TBI and cultured for 24 hrs. Annexin V staining was 
equivalently as high as in Tregs irradiated ex vivo. Further analysis 
following ex vivo irradiation indicated that apoptotic ells were 
evident between 4 and 8 hours post-exposure. Since >90% of 
Tregs exposed to a dose of 3.0Gy are undergoing apoptosis by 24 
hrs, and these cells did not lose the entirety of their regulato W 
function, four hours after 3.0 Gy, irradiated Tregs were co-cul- 
tured with anti-CD3 and CD25- responding cells to determine the 
kinetics of function post-irradiation. These Tregs failed to exhibit 
any regulatory activity. It may be notable that 24 hrs following 
busulfan treatment (30mg/kg) of B6 mice, CD4+CD25 + Treg ceils 
maintained their ability to regulate CD4 T cell proliferation, in 
total, these observations suggest that immediately following doses 
of ->3.0Gy Treg survival and function appear to be compromised. 
Additionally, alternative conditioning regimens may differentially 
affect he functional capacity of host Treg cells following BMT. 
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THE INFLUENCE OF THE GRAFT MONOCYTES IN THE OUTCOME OF 
ALLOGENEIC BONE MARROW TRANSPLANTATION 
Pe1~teaclo Ara~ha, F.J.; P'igot-ito, A.C.; De Soztza, C.A.; Bo~'ba 
Oliveira, G.; Brito Eicl, K.A.; Zzdli, R.; Lo~:aml-Met~e, L Bm~e Mar- 
7"ow Tra*zsp/a~m~tio*z, State Ut~iz,eJ'si U of Campit~as, Campmas, Sao 
Pazllo, B*'azil. 
Francisco J P Aranha, Afonso C Vigorito, Carmino A De Sousa, 
Gislaine B Oliveira, Katia A Eid, Roberto Zulli, Irene Lorand- 
Metze Bone Marrow Transplantation Unit State University of 
Campinas, SP/Brazil The influence of graft monocytes on GVHD 
has not yet been established in clinical trials.V~te valuated the 
influence of bone marrow graft monocytes aiming, primarily, to
analyse the correlation with aGVHD and cGVHD, and secondar- 
ily with engra~nent and survival. Eligibility criteria age <60 years; 
patients with primary malignant or non-malignant hematological 
disease receiving BM from an HLA-identical sibling. We analyzed 
83 patients. Conditioning was mainly BuCy2 and GVHD prophy- 
laxis CSA-MTX. The median day to reach peripheral leukocytes _> 
0.5x109/1 and platelet count >20x109/1 was 20 (I 1-34) and 18.5 
(10-60) respectively. In univariate analysis, any parameter was cor- 
related with a faster engrafinent. The frequency of a-GV-HD, 
grades 2-4 was 12/83 (i4.5%). In univariate analysis, TNC 
>2.31x108/Kg and CD14+ cells >4.78x106/Kg were correlated 
significantly with lower rates of a-GVHD (p=0.04, p=0.02, respec- 
tively). Furthermore, patients >27 years old and donor gender 
mismatch ad higher rates of aGVHD (p=0.03 and p=0.04, 
respectively). In a nmltivariate analysis, both TNC and age main- 
tain significance for lower risk of a GVHD. The probability was 
3.2% when age < 27 years and TNC infused _> 2.?1 X 108/Kg. A 
higher risk of a-GVHD was found (51.5%) when age > 27 years 
and TNC infused < 2.31 X 108/Kg (P<0.001).The number of 
CD14+ cells showed a correlation with TNC. This interaction 
might be the cause for the loss of significance for monocytes in 
the multivariate analysis. Clinical c GVHD of all grades devel- 
oped in 31/77 (40%) available patients. It was extensive in 20 cases 
and limited in 11 cases. In univariate analyses there was a correla- 
tion between previous a-GVHD and a higher risk of c-GVHD 
(p<0.001). CD14+ cells did not influence c-GVHD. The estimate 
of 6-year overall survival (OS) was 66% (95% CI: 55%-79%). In 
univariate analyses, the absence of a GVHD was correlated with a 
higher survival (p<0.001). Furthermore, there was a trend for a 
better survival in patients receiving more CD34+ cells (p=0.06). 
The CD14 cells had no impact on overall survival. These prelimi- 
nary data suggest that CD14+ cells may have a protective ffect in 
allogeneic BMT. 
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TNF TYPE II RECEPTOR GENOTYPE AFFECTS SOLUBLE RECEPTOR 
LEVELS IN NORMAL SUBJECTS AND ASSOCIATES WITH CHRONIC 
GVHD SEVERITY 
Stark, G. l; DickitlsoJ?, A.M. ~; ffaclesoJ~, G.H.e; Taylor, P.R. "-; Middle- 
to~, P.G. I 1. U'nive~-sity ofNewcastle, Newcastle Hpo~ Tyze, Ul~ited 
KtJagdom; 2. Royal f'tcto*'ia llz/;JwlaJty , Newamle elpo,z Ty,le, U'Mted 
Ki~gdom. 
A single nucleotide polymorphism in the TNF type II recep- 
tor(TNFRII) gene, at codon 196, results in the substitution f 
arginine (R allele) for methionine (M allele). The R allele is 
reported to associate with susceptibility to autoimmune disease 
and donor R allele carriage correlates with acute graft-versus-host 
disease (GVHD) severity after MUD BMT. To investigate the 
functional impact of this polymorphisln, 81 volunteer blood 
donors were genotyped by PCR and SSCP analysis and soluble 
TNFRII (sTNFRII) levels were measured by ELISA. Mean (+/- 
SEM) plasma sTNFRII levels were 1225+/-26 and I063+/-65 for 
individuals caruing at least 1 M allele (M+) and RR homozygotes 
respectively (p=0.02). We examined the impact of this polymor- 
phism on acute and chronic GVHD incidence/severity after non- 
T ceil-depleted sibling BMT. TNFRII 196 M/R genotype was 
determined amongst 106 transplant recipients, 106 donors and 
131 control subjects. R allele frequency amongst recipients, 
donors and controls was 0.28. In univariate analysis there was a 
trend towards increased acute GVHD incidence [odds ratio (OR) 
2.9] amongst R+ recipients (p=0.1). In nmltivariate analysis by 
logistic regression, correcting for established clinical and genetic 
GVHD risk factors, the impact of recipient TNFRII  R+ status 
was reduced (p=0.13). In univariate analysis, donor RR homozy- 
gosity associated with a trend to increased cGVHD incidence (OR 
4.6; p=0.1) and an increased risk of extensive cGVHD (OR 8.5; 
p=0.01). In nmltivariate analysis donor RR homozygosity associat- 
ed with an increased risk of extensive cGVHD (relative risk 11.3; 
p=0.02) but not cGVHD incidence per se. Since sTNFRIIs can 
act as TNF  antagonists, the association between donor RR 
homozygosity and cGVHD may reflect reduced circulating sTN- 
FRII. The role for pharmacological interventions, particularly the 
use of recombinant sTNFRII (Etanercept) requires further inves- 
tigation, but may be influenced by genotype. 
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RAPID ENGRAFTMENT IS ASSOCIATED WITH AN INCREASED INCI- 
DENCE OF GRAFT VS HOST DISEASE (GVHD) IN CHILDREN FOLLOW- 
ING REDUCED-INTENSITY HEMATOPOIETIC STEM CELL TRANSPLAN- 
TATION (RI-HSCT) 
B~wck~le~; L.1; D'lm1"st, R?, K_letzel, ~[.2 i. Golismm Ch//ch'e77 ;" Hos'pi- 
tnl, UJdversitv of Roc,~este1" Medical Celzter, Rochestel; NY," 2. C,~ttctlw~s 
3/iemo~'ial Hospital, Nol-tbwestelw Utlivevsity, Chicago, IL. 
We conducted a retrospective chart review of I9 children who 
had undergone RI-HSCT at Childrens Memorial Hospital over 
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